Figure 5.
Figure 5. Donor versus no-donor analysis on relapse-free survival according the combined NPM1 and FLT3 ITD mutation status. (A) NPM1-mutated/FLT3 ITD–negative patients. (B) All other patients.

Donor versus no-donor analysis on relapse-free survival according the combined NPM1 and FLT3 ITD mutation status. (A) NPM1-mutated/FLT3 ITD–negative patients. (B) All other patients.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal